• Invest
    Investment Suite
    Stocks
    Mutual Funds
    Future and Options
    IPO
    Exchange Traded Funds
    Commodity
    Stockcase (Stock Baskets)
    Currency
    Non Convertible Debentures
    Sovereign Gold Bond
    Exclusive
    NRI Account
    Private Client Group
    Features
    SipIt
    MTF
    Investment Suite
    Exclusive
    Features
  • Platform
    Product Suite
    Kotak Neo App & Web
    Nest Trading Terminal
    NEO Trade APIs
    Features and Tools
    MTF
    Securities Accepted as Collateral
    Margin Requirements
    Equity Screeners
    Payoff Analyzer
    Calculators
    SIP Calculator
    Lumpsum Calculator
    Brokerage Calculator
    Margin Calculator
    MTF Calculator
    SWP Calculator
    CAGR Calculator
    Simple Interest Calculator
    ELSS Calculator
    Step up SIP Calculator
    All Calculators
    Product Suite
    Features and Tools
    Calculators
  • Pricing
  • Research
    Research Calls
    Long Term calls
    Short Term calls
    Intraday calls
    Derivatives calls
    Pick of the week
    Top Monthly Picks
    Research Reports
    Fundamental Research Report
    Technical Research Report
    Derivative Research Report
    Research Calls
    Research Reports
  • Market
    Stocks
    Market Movers
    Large Cap
    Mid Cap
    Small Cap
    Indices
    Nifty 50
    Bank Nifty
    FinNifty
    Nifty Midcap India
    VIX
    All Indian Indices
    Mutual Funds
    SBI Mutual Funds
    HDFC Mutual Funds
    Axis Mutual Funds
    ICICI Prudential Mutual Funds
    Nippon India Mutual Funds
    All AMC's
    IPO
    Upcoming IPO
    Current IPO
    Closed IPO
    Recently Listed IPO
    Stocks
    Indices
    Mutual Funds
    IPO
  • Learn
    Resource
    Market Ready
    Kotak Insights
    Infographic
    Podcast
    Webinars
    Youtube Channel
    Quarterly Results
    Investing Guide
    Demat Account
    Trading Account
    Share Market
    Intraday Trading
    IPO
    Mutual Funds
    Commodities
    Currency
    Futures & Options
    Derivatives
    Margin Trading
    Events
    Budget 2024
    Muhurat Trading
    Share Market Holiday
    Market Outlook 2025
    Resource
    Investing Guide
    Events
  • Partner
    Business Associates
    Fund Expert
    Kotak Connect Plus
    Startup connect
  • Support
    FAQs
    Circulars
    Bulletins
    Contact Us
    Forms Download
    Get your Statement

₹ 14823 / 27 shares

IPO Details

RHP/DRHP

Issue Date

11 Dec - 13 Dec'24

Investment/lot

₹ 14823

Price Range

522 - 549

Lot Size

27

IPO Size

₹ 2939.7 - ₹ 3042.62 Cr

Start date

End date

Allotment of bids

Refund Initiation

Listing on exchange

Sai Life Sciences IP is an IPO of ₹3042 crores. It consists of a fresh issue portion of ₹950 crores and an offer for sale of ₹2092.62 crores. The date for anchor bidding is Dec 10, 2024. The shares will be allotted on Dec 16, 2024. The initiation of refunds will take place on Dec 16, 2024 and the shares will be credited to the demat account on Dec 17, 2024.

  • Repayment or prepayment of certain borrowings: ₹720 crores.
  • General corporate purposes
Particulars Value
Upper Price Band
₹549
Existing Shares To be sold
38,116,934 shares
Fresh Issue
17,204,189 shares
Market Cap
₹11419 crores
EPS
45.28
Application Lots Shares Amount
Retail (Min)
1
27
₹14,823
Retail (Max)
13
351
₹192,699
S-HNI (Min)
14
378
₹207,522
S-HNI (Max)
67
1809
₹993,141
Subscription Details Percentage
QIB
50%
NII
15%
Retail
35%
Name of the company Revenue from Operations Face Value per equity share P/E Ratio EPS Basic RoNW NAV per equity share
Sai Life Sciences Limited
14651.78
1
*
4.57
8.50%
53.83
Divi’s Laboratories Limited
78,450.00
2
103.04
60.27
11.79%
511.21
Suven Pharmaceuticals Limited
2391.73
1
109.37
11.80
14.64%
94.04
Syngene International Limited
10,513.54
10
73.59
12.69
11.98%
105.91

The anchor investors’ bid opens on Dec 10, 2024. The company may allocate up to 60% of the QIB portion to anchor investors, out of which one third will be allocated to Mutual Funds.

Book running lead managers:

  • Kotak Mahindra Capital Company Limited
  • Jefferies India Private Limited
  • Morgan Stanley India Company Ltd
  • IIFL Securities Ltd

Registrar for the IPO: Kfin Technologies Limited

The company earns money from the following sources:

  • Contract Research: Research services for small molecule development.

  • Contract Manufacturing: Large-scale production of APIs and intermediates.

  • Fee-for-Service (FFS) Model: Revenue based on customer-specific projects and long-term contracts.

Revenue from operations increased from ₹8,691.24 million in FY22 to ₹14,687.23 million in FY24. Profit after tax surged from ₹62.26 million in FY22 to ₹828.09 million in FY24.

Sai Life Sciences is a leader in the global CRDMO market, which is forecasted to reach USD 159 billion by 2028. The Indian CRDMO sector, growing at 14% CAGR, positions the company as a significant player with a strong focus on small molecule research and cost-efficient services.

The global small molecule Contract Research, Development, and Manufacturing Organisation (CRDMO) market is projected to reach USD 159 billion by 2028, driven by rising pharmaceutical and biotech R&D outsourcing and demand for cost-efficient drugs. India’s CRDMO market is among the fastest-growing in the Asia-Pacific region, with an anticipated 14% CAGR between 2023 and 2028, reaching USD 14.1 billion by 2028. The industry's growth is fuelled by advancements in drug discovery, manufacturing technologies, and a strong focus on small molecule therapeutics.

Sai Life Sciences is a fully integrated, innovator-focused contract research, development, and manufacturing organisation (CRDMO). The company provides end-to-end services for small molecule new chemical entities to pharmaceutical innovators and biotech firms globally.

Comprehensive financial data, including revenue, profit/loss statements, EBITDA, and other critical metrics.

Particulars (in Rs. million)

Particulars (in Rs. million)

Presentation of key financial metrics and indicators to assess Sai Life Sciences's financial health.

Metric FY22 FY23 FY24
Revenue from Operations
8,691.24
11,969.49
14,687.23
Total Equity and Liabilities
22,751.36
21,866.48
21,642.30
RoNW (%)
0.71
1.13
8.5

Regulatory Dependencies: Highly dependent on obtaining and maintaining licenses and approvals.

Market Competition: Faces intense competition in the global CRDMO space.

Financial Risks: Exposure to foreign exchange fluctuations and raw material price volatility.

Potential Benefits for Investors:

  • Access to the fast-growing Indian CRDMO market, projected to grow at 14% CAGR.
  • Leveraging Sai Life’s established global presence in drug discovery and manufacturing.

Sai Life Sciences is a leader in the global CRDMO market, which is forecasted to reach USD 159 billion by 2028. The Indian CRDMO sector, growing at 14% CAGR, positions the company as a significant player with a strong focus on small molecule research and cost-efficient services.

One of the largest integrated Indian CRDMOs in terms of revenue from operations for the Financial Year 2024acting as a one-stop platform for discovery, development and manufacturing

The company is one of the largest integrated CRDMOs among listed Indian peers in terms of revenue from operations for the FY2024, serving as a one-stop platform for discovery, development and manufacturing. (Source: F&S Report).

CDMO platform with a diverse mix of commercial and under-development molecules:

We provide end-to-end development and manufacturing services covering the full value chain for intermediates and APIs.

As of September 30, 2024, the company’s development and manufacturing portfolio constituted 38 products used in the production of 28 commercial drugs, including seven blockbusters (drug products with annual sales of over US$1 billion in the Financial

Year 2023) and 12 products used in the production of 11APIs that were either undergoing or had completed Phase III clinical trials (Source: F&S Report).

Consistent Growth: Demonstrated revenue and profitability growth over the past three years.

The company is the fastest-growing Indian CRDMO among listed Indian peers in terms of revenue CAGR as well as EBITDA CAGR from Financial Year 2022 to Financial Year 2024. (Source: F&S Report) This growth is complemented by a trend of improving margins. Their strategic initiatives which are focused on operational efficiencies, cost management, and value creation allow them to not only grow but also improve their profitability and return on capital.

(in millions) FY24 FY23 FY22
Profit/loss before tax
1092.34
164.08
96.95
Net cash generated from/using operating activities
2,630.87
2 ,194.03
1048.66
Net Cash generated from investing activities
(1,923.81)
(1,017.81)
(1,037.14)
Net cash generated from financing activities
(952.99)
(2,006.48)
719.23
Cash and cash equivalent at the end of the year
119.69
3 55.29
(736.54)

You can check the allotment status of shares either on the website of the Bombay Stock Exchange (BSE) or on the website of the registrar — Link InTime India Pvt Ltd. To check the status on the BSE website:

  • Visit the BSE website
  • Click on “Investor Services” and choose “Application Status Check”
  • Choose the issue type — Equity or Debt (Equity in this case)
  • Select the Issue Name from the drop-down. The issue name is the company’s name, which is Sai Life Sciences Ltd
  • Enter your application number or PAN number
  • Check the box which says “I’m not a Robot” and click on “Search” to know the allotment status

Follow these steps to know the allotment status on the registrar’s website:

  • Visit the Link Intime website
  • Choose “Public Issues” from the “Investor Services” drop-down
  • Select Sai Life Sciences from the drop-down
  • Enter your PAN number or Application number
  • Click on “Submit” to know the allotment status
WATCH AND LEARN
All you need to know about Sai Life Sciences IPO
Sai Life Sciences Limited has announced its IPO to make its debut in the Indian stock market. The company researches, develops, and manufactures small-molecule new chemical entities. They offer tailor-made services to biotech firms and global pharma companies.

Sai Life Sciences IPO FAQs

The minimum lot size is 27 shares and the investment required is ₹14823.

The price band of Sai Life Sciences IPO is ₹522 to ₹549.

You can read more about Sai Life Sciences and its IPO from the company’s red herring prospectus (RHP) here.

The Sai Life Sciences Diagnostics Limited IPO has an issue size of ₹3042 crores. The IPO opens for subscription on 11/12/2024 and closes on 13/12/2024.

Link Intime India Limited is the registrar for this IPO.

Open Demat Account to Invest in any IPO
+91 -

personImage
Open Demat Account to Invest in any IPO
+91 -